We have previously demonstrated that Cyclin A2 is involved in cytoskeletal dynamics, epithelial-mesenchymal transition (EMT) and metastasis. This phenotype was potentiated by activated oncogenic H-Ras. However, the mechanisms governing EMT in these cells have not yet been elucidated. Here, we dissected the pathways that are responsible for EMT in cells deficient for Cyclin A2. In Cyclin A2-depleted normal murine mammary gland (NMuMG) cells expressing RasV12, we found that β-catenin was liberated from the cell membrane and cell-cell junctions and underwent nuclear translocation and activation. Components of the canonical wingless (WNT) pathway, including WNT8b, WNT10a, WNT10b, frizzled 1 and 2 and TCF4 were upregulated at the messenger RNA and protein levels following Cyclin A2 depletion. However, suppression of the WNT pathway using the acetyltransferase porcupine inhibitor C59 did not reverse EMT whereas a dominant negative form of TCF4 as well as inhibition of phospholipase C using U73122 were able to do so. This suggests that a WNTindependent mechanism of β-catenin activation via phospholipase C is involved in the EMT induced by Cyclin A2 depletion. Our findings will broaden our knowledge on how Cyclin A2 contributes to EMT and metastasis.
Introduction
Cyclin A2 is known as a regulator of S phase progression and the G2/M transition in association with cyclin-dependent kinase 1 and cyclin-dependent kinase 2 (1). However, depending on the cell type, its cell cycle-related functions can be compensated by Cyclin E (2). We have recently discovered novel roles of Cyclin A2 that are associated with its cytoplasmic localization and independent of its association with the cyclin-dependent kinases (3) . More specifically, we have shown that Cyclin A2 depletion in fibroblasts leads to an increase in cell motility and cooperates with oncogenic transformation to increase invasiveness in collagen matrices (4) . Moreover, Cyclin A2 protein levels are much lower in highly invasive colon adenocarcinoma cell line derived from metastases with respect to its low invasive counterpart derived from the primary tumor. Importantly, this is also seen in matched human samples obtained from metastatic sites or from primary colon adenocarcinomas, which suggest that a decreased expression level of Cyclin A2 could be linked to cancer metastasis (4) . Our previous findings also demonstrated that Cyclin A2 knockdown induces an epithelial to mesenchymal transition (EMT) in RasV12-transformed mammary epithelial cells and increases their invasiveness in vitro as well as in vivo (5) . Further, these cells are more resistant to anoikis and form tumorspheres under non-adherent conditions. Although we found that the Rho GTPases, RhoA and RhoC are responsible for the invasion phenotype induced by Cyclin A2 inactivation, and RhoA is involved in the maintenance of cell-cell junctions, they do not fully account for the EMT phenotype that we observed in Cyclin A2-depleted cells (5) .
EMT is a normal biological process that is important for organogenesis and wound healing and has recently emerged as a leading concept to explain metastasis (6) . This process entails the transdifferentiation of epithelial cells to mesenchymal cells, which promotes their displacement. Oncogenic EMT, which is thought to arise during tumorigenesis, is generally characterized by a decrease and/or a delocalization of epithelial markers [E-cadherin (ECAD), occludin], upregulation of mesenchymal markers [N-cadherin (NCAD), vimentin] and transcriptional factors (Zeb1/2, Slug, Snail, Twist1/2, etc), as well as functional attributes such as increase in migration, invasion, cell scattering and resistance to anoikis (7) .
Multiple signaling pathways are known to be dysregulated during tumorigenesis and EMT. Among them, the WNT pathway has been shown to play a major role in metastasis and promotion of EMT in breast cancer, in which expression of WNT ligands or suppression of their inhibitors induces EMT and metastasis (8, 9) . The canonical WNT signaling pathway is initiated by binding of a WNT ligand to a frizzled (FZD) receptor and its associated co-receptors, low-density lipoprotein receptor-related proteins 5/6 (LRP5/6). This inactivates glycogen synthase kinase-3β (GSK-3β) via phosphorylation, followed by the release, dephosphorylation (at serine 37 or threonine 41) and nuclear translocation of β-catenin, where it binds to T-cell factor (TCF)/lymphocyte enhancer factor components and activate transcription of target genes, such as the mesenchymal marker, fibronectin (10) .
β-catenin is also known to be regulated independently of the WNT pathway, through inactivation of GSK-3β and/or delocalization of ECAD, which ultimately liberates β-catenin to undergo dephosphorylation and nuclear translocation. Some reports have shown that WNT-independent β-catenin regulation can occur through transduction components such as extracellular signal-regulated kinases 1 and 2 (ERK1/2), protein kinase A (PKA), protein kinase B (AKT1), as well as phospholipases A and C isoforms (11) (12) (13) (14) (15) .
Recently, phospholipase C (PLC) isoforms have been shown to be major players in EMT, mainly in metastatic breast cancer cells, due to their roles in regulating cytoskeletal organization, differentiation and other signal transduction pathways (16) . Interestingly, isoforms of PLC are known to be activated by Rho GTPases (17, 18) , and PLC-γ is also regulated by the ECAD/β-catenin complex at the plasma membrane (19) .
In light of all these recent findings, we elucidated the mechanisms that modulate the EMT process and β-catenin activation in RasV12-transformed murine mammary gland epithelial (NMuMGRasV12) cells in which Cyclin A2 was ablated.
Material and methods

Plasmids
The sequence of the short hairpin RNA targeting Cyclin A2 used for all experiments is: 5′-GTAGCAGAGTTTGTGTATA-3′. The control was a scrambled (sh-scramble) sequence, and they were both cloned into RNAi-Ready pSIREN-RetroQ vector (Clontech, Mountain View, CA). The plasmid containing dominant negative TCF4 (dnTCF4) and the recombinant protein GST-TCF1 were kind gift from L. Grumolato (University of Rouen, Mont Saint Aignan, France).
Retrovirus production
The human embryonic kidney HEK293T cells were used for virus packaging and production. These cells were plated in 10 cm dishes and 1 μg each of vectors encoding for GAG-POL and an ecotropic murine leukemia virus envelope protein with either 3 μg of plasmids coding for shCyclin A2 or scrambled were transfected using jetPEI (Polypus, Illkirch, France). The supernatant was removed the next day and the cells were transfected again with the same vectors. The supernatant containing the virus was subsequently collected 24 h later, passed through 0.45 μm filters and stored at −80°C until use.
Cell culture, transfections, infections and treatments
NMuMG cells from ATCC were obtained in 2010 and were tested using short tandem repeat profiling. Cells were expanded and stocks were frozen down at no more than five passages following reception. After thawing, they were used no more than 30 passages in culture, for example <3 months. New batches of cell were regularly thawed. Cells were immediately transfected after thawing with a vector expressing H-RasV12 to produce the stable cell line, NMuMGRasV12, as described previously (5), which was maintained in Dulbecco's-modified Eagle's medium medium with 10% fetal calf serum and insulin (10 μg/ml). For virus infection, NMuMGRasV12 cells were incubated with virus-containing supernatant for 24 h in the presence of polybrene (10 μg/ml) (Sigma-Aldrich, St. Louis, MO), then selected with 2 μg/ml puromycin (Invitrogen, Carlsbad, CA). NMuMGRasV12 cells were transfected with the dnTCF4 or control vector using X-treme GENE HP DNA Transfection Reagent (Roche, Basel, Switzerland) and harvested at 48-72 h. The following are the reagents that were used to treat the cells: 10 μM AACOCF3 (Millipore, Billerica, MA), 10 μM U0126 (Promega, Madison, WI), 10 μM H89 (Sigma-Aldrich), 10 μM C59 (Cellagen Technology, San Diego, CA) and 1 μM U73122 (Sigma-Aldrich). Dimethyl sulfoxide (DMSO) (SigmaAldrich) was used as the dissolvent and vehicle control.
Antibodies
The following antibodies were used for immunoblotting: monoclonal antiCyclin A2 (Sigma-Aldrich, clone CY-A1, 1:200 dilution), anti-phosphorylated AKT (Cell Signaling Technology, Danvers, MA, #9271, 1:1000 dilution), anti-phosphorylated stress-activated protein kinase/jun-amino-terminal kinase (SAPK/JNK) (Cell Signaling, #9255, 1:1000), anti-phosphorylated ERK1/2 (Cell Signaling, #9101, 1:1000), anti-phosphorylated GSKα/β (Cell Signaling, clone D17D2 #8566, 1:1000), anti-total AKT1 (Cell Signaling, clone C73H10, #2983, 1:1000), anti-total SAPK/JNK (Cell Signaling, #9252, 1:1000), anti-total ERK1/2 (Cell Signaling, #9102), anti-total GSKα/β (Cell Signaling, clone D75D3, #5676), anti-total β-catenin (BD 
Western blotting
Protein samples were harvested directly with 5× Laemmli buffer, separated in sodium dodecyl sulfate-polyacrylamide gels and electroblotted onto nitrocellulose membranes (Millipore) using a wet/tank transfer system (Bio-Rad, Hercules, CA). Densitometric quantitation of at least three immunoblots was carried out using the ImageJ software (National Institute of Health). The data are shown as relative units where control bands were given a value of 1, and experimental values as fold change over control following normalization with glyceraldehyde 3-phosphate dehydrogenase or histone A2 for pull-downs. All the experiments were performed in triplicate and at least three times.
Quantitative real-time PCR
RNA was purified using RNeasy kit (Machery-Nagel, Dueren, Germany) and treated with DNase as per the manufacturer's protocol. Reverse transcription was performed using Superscript III (Invitrogen) according to standard protocol. qPCR (quantitative real-time PCR) was performed using SYBR Green (Roche) with the primers listed in Table 1 . Briefly, 1 μg of RNA was used to generate 20 μl of complementary DNA, following which the complementary DNA samples were diluted and then subjected to 45 cycles of PCR at 95°C for 10 s and 60°C for 15 s. Internal controls used were GUS (β-glucuronidase), HPRT (hypoxanthine guanine phosphoribosyl transferase 1) and TBP (TFIID TATA box binding protein).
Reactions were performed on a LightCycler 480 (Roche) machine. Data are shown as relative units where control bands were given a value of 1 and experimental values as fold change over control following normalization with the three housekeeping genes. All the experiments were performed in duplicate and at least three times. Primers sequences are depicted in Table 1 Immunofluorescence
Prior to IF analysis, cells were fixed 30 min in 100% ethanol (−20°C) then a few seconds in acetone or with 1:1 ratio of methanol and acetone for 10 min at −20°C. Fixed cells were incubated with anti-ECAD, anti-NCAD or anti-total β-catenin at room temperature for 2 h, followed by secondary antibody for 1 h and finally counterstained with Hoechst 33342. The staining was viewed using AxioImager Z1 (Carl Zeiss, Oberkochen, Germany) with 63× Plan-Apochromat 1.4 oil lenses (Carl Zeiss). Images were collected using a CoolSnap HD2 charge-coupled device camera (Roper Industries, Sarasota, FL) driven by MetaMorph 7.1 Software.
β-catenin pull-down assay
Cells were lysed with Nonidet-P40 lysis buffer [20 mM Tris, 100 mM ethylenediaminetetraacetic acid, 100 mM ethyleneglycol-bis(aminoethylether)-tetraacetic acid, 150 mM NaCl, Complete protease inhibitor (Roche) and 1% NP-40]. Glutathione agarose beads (Thermo Scientific, Waltham, MA) were incubated for 45 min at room temperature with glutathione S-transferasetagged TCF1, then washed thoroughly. The beads were then mixed with 0.5-1 mg of protein lysates, incubated overnight at 4°C and washed thoroughly. The pellet was mixed with 5× Laemmli buffer and subjected to electrophoresis and western blotting.
TOP/FOP reporter assay
TOPFlash and FOPFlash plasmids with the firefly luciferase reporter were provided by Dr Randall Moon (University of Washington, Seattle, WA), and the plasmid coding for S33Y β-catenin was provided by Dr Eric Fearon (University of Michigan, Ann Harbor, MI). shScr and shCycA2 cells were transfected with the TOPflash or FOPflash plasmid and a pcDNA3 plasmid coding for the Renilla Luciferase under the control of the Cytomegalovirus promoter (using a 10:1 ratio of the DNA quantity in comparison to the TOP or FOP plasmid) for normalization. For the S33 β-catenin condition, the plasmid coding for the stable β-catenin bearing the S33Y mutation was cotransfected with the TOPflash or FOPflash plasmid. 24 h later, the cells corresponding to the Wnt3a condition were stimulated using 50 ng/ml of Wnt3a ligand. All the cells were collected 24 h later, lysed in PLB buffer and analyzed using the Dual Luciferase Reporter Assay system (Promega) according to the manufacturer's instructions.
Subcellular fractionation
The Compartmental Protein Extraction kit (Chemicon, Temecula, CA) was used to separate the nuclear fraction of the cells, as per the manufacturer's protocol.
Statistical analysis
Data are reported as arithmetic means ± SEM. Statistical analyses were carried out using Student's t-test or Mann-Whitney's U-test, where appropriate, performed with Prism software. Statistical significance was defined as P ≤ 0.05.
Results
We previously showed that reduced expression of Cyclin A2 at the protein level is observed in metastatic human tumors, and its inactivation in epithelial cell lines leads to EMT, in correlation with increased invasion and extravasation in cell culture and animal models, respectively. To elucidate the mechanisms that govern these effects, we first investigated the different signal transduction pathways shown previously to be involved in EMT, by either screening for the activated forms of AKT1, SAPK/ JNK, ERK1/2 and GSK-3β or using chemical inhibitors. Herein, we used a system in which overexpression of the oncogene H-RasV12 initiated EMT and Cyclin A2 depletion accentuated this phenomenon, as described previously (5).
ERK1/2 pathway does not play a role in Cyclin A2 depletion-induced EMT
As shown in Figure 1A by western blot analysis, the levels of phosphorylated ERK1/2 were increased in Cyclin A2-depleted NMuMGRasV12 (shCycA2) cells indicating higher activities of the kinases, whereas increased phosphorylation of GSK3β reflected its reduced activity. Further, the activity levels of AKT1 and SAPK/JNK were also investigated, however, no change in the protein level of the active phosphorylated form of AKT1 was observed, whereas activation and phosphorylation of SAPK/ JNK was decreased (Supplementary Figure 1 , is available at Carcinogenesis Online). We decided to explore further the contribution of ERK1/2 to our EMT model by using U0126, the pharmalogical inhibitor of mitogen-activated kinase kinases1/2, which are the upstream regulators of ERK1/2. As shown in our previous report, Cyclin A2 depletion in NMuMGRasV12 cells decreased the epithelial marker ECAD, while increasing the mesenchymal markers NCAD and fibronectin (Figure 1B , left; all P < 0.0001).
In shCycA2 cells treated with U0126, we found that all 3 messenger RNA (mRNA) levels were increased (Figure 1B, right; all P < 0.0001), whereas ECAD and NCAD protein levels remained similar as compared with vehicle-treated shCycA2 cells ( Figure 1C) . We further checked ECAD localization and organization by IF after U0126 treatment in comparison with controls ( Figure 1D ). The phenotype of Cyclin A2-depleted cells treated with U0126 was similar to the vehicle-treated condition, indicating an absence of effect of the U0126 inhibitor on EMT induced by Cyclin A2 inactivation. Both conditions harbored an increase in cytoplasmic ECAD and nonsmooth staining of cell-cell junctions as compared with control cells.
β-catenin and WNT pathway are activated by Cyclin A2 depletion
We showed that GSK3β was phosphorylated, that is, deactivated, following Cyclin A2 depletion ( Figure 1A ), which could indicate activation of the canonical β-catenin/WNT pathway. We therefore verified the cellular localization and activation status of β-catenin using several experimental approaches. First, we performed IF labeling of β-catenin in control and Cyclin A2-depleted NMuMGRasV12 cells, which showed some membrane staining, but as shown in Figure 2A , cells lacking Cyclin A2 harbored increased β-catenin nuclear localization (arrows) in comparison with control cells. To verify its translocation and nuclear accumulation, we performed subcellular fractionation and were able to confirm by western blot analysis that active β-catenin protein levels were increased in the nuclear fraction of shCycA2 cells versus control ( Figure 2B ; P = 0.04). We next performed a β-catenin pull-down using glutathione S-transferase-tagged TCF1 as bait, the latter being the transcriptional factor component that binds to dephosphorylated and activated β-catenin (20) . As shown in Figure 2C , there was a higher level of active β-catenin in Cyclin A2-depleted cells relative to control (P = 0.05). We then assessed for β-catenin transcriptional activity by transfecting the TOPflash and FOPflash plasmids and measuring the luciferase activity in shScr and shCycA2 cells. As positive control for our experiment, cells were cotransfected with a plasmid encoding for the constitutively active β-catenin mutated at S33Y or were stimulated by Wnt3a ligand. As shown in Figure 2D , luciferase activity was increased in shCycA2 cells (P = 0.03), after transfection with S33Y β-catenin (P = 0.002) or following treatment with Wnt3a (P = 0.02) as compared with their respective controls. Finally, we performed qPCR analysis for the Wnt targets Myc, Snail and Axin2, and observed an increased proportion of mRNA coding for Myc (P = 0.008) and Snail (P = 0.04), whereas Axin2 appeared decreased following Cyclin A2 inactivation ( Figure 2E ). We next checked whether some components of the WNT pathway were induced in the absence of Cyclin A2. qPCR analysis of mRNAs coding for WNT8a, WNT10a, WNT10b, TCF4, FZD1, FZD2, secreted frizzled-related protein 2 (SFRP2) and SFRP4 showed a significant increase of these transcripts in Cyclin A2-deficient cells ( Figure 2F ), but no significant alterations for WNT2, 2b, 4, 5b, 9a, 9b, FZD4-6, LRP5-6, SFRP1-5 and β-catenin mRNAs as compared with control ( Supplementary Figure 2 , is available at Carcinogenesis Online). WNT1, WNT3, WNT8b, FZD3, FZD5 and SP5 were not expressed or at an undetectable level. We observed increased protein levels of FZD1 and FZD2 that thus correlated with their mRNA upregulation ( Figure 2G ). Altogether, these findings suggest that the canonical WNT pathway is activated in the absence of Cyclin A2.
Inhibition of the WNT pathway only partially counteracts Cyclin A2 depletion-induced EMT whereas β-catenin inhibition reverses it
In order to validate the role of the WNT pathway in EMT promoted by Cyclin A2 deficiency, we treated Cyclin A2-deficient cells with C59, an inhibitor of the WNT acyltransferase porcupine which blocks palmitoylation, secretion and biological activity of WNT ligands. We then investigated the transcript levels of various EMT markers, including ECAD, NCAD, matrix metalloproteinase 3 (MMP3), E12, E47 and Twist2 by qPCR. Although ECAD was increased (P = 0.004) and MMP3 mRNA was downregulated (P < 0.0001) by C59 treatment, the other markers remained unchanged ( Figure 3A and Supplementary Figure 3 , is available at Carcinogenesis Online). At the protein level, ECAD was expressed at the same level as vehicle control, although NCAD was decreased (P = 0.009) ( Figure 3B ). We then performed IF analysis to determine the status of ECAD in Cyclin A2-depleted cells treated with the C59 compound in comparison with vehicle control cells. Even after C59 treatment, the cells harbored a disruption of cellcell junctions and mainly cytoplasmic localization of ECAD similar to shCycA2 cells treated with DMSO, although the cell shape of C59-treated cells reverted to a more cuboidal morphology that is typical of epithelial cells ( Figure 3C ). This indicates that while some EMT parameters were reverted by blocking the upstream components of the WNT pathway, the full EMT process could not be reversed. β-catenin can be regulated by WNT-independent pathways, especially when there is disruption of ECAD. We therefore determined whether it was active at the transcriptional level by transfecting Cyclin A2-deficient cells with a dnTCF4, which is normally a key binding partner of the β-catenin transcriptional complex. Expression of dnTCF4 would impede any β-catenin transcriptional activity and its downstream effects since it can no longer bind to β-catenin. qPCR analysis detected an increase in ECAD mRNA while both NCAD and fibronectin were downregulated when comparing levels in dnTCF4 transfected cells to shCycA2 cells ( Figure 3D ; P = 0.002, P < 0.0001, P = 0.0002, respectively). Further, Although ECAD protein level as assessed by immunoblotting was slightly increased (P = 0.008), NCAD expression was reduced (P = 0.02) ( Figure 3E ). More notably, ECAD localization and organization as shown by IF were improved in Cyclin A2-deficient cells transfected with dnTCF4 as compared with vehicle control (Figure 3F) . Therefore, β-catenin appears to be a crucial molecule in regulating the EMT phenotype induced by Cyclin A2 deficiency, but through a β-catenin-dependent WNT-independent mechanism. . All experiments were performed at least 3 times. mRNA levels were normalized to GUS, HPRT and TBP, and protein levels were normalized to GAPDH. *P < 0.05, **P < 0.01, ***P < 0.001. Scale bars = 20 μm.
PLA and PKA partially contribute to EMT promoted by Cyclin A2 depletion
Phospholipase A (PLA) and PKA have previously been shown to play important roles in WNT-independent β-catenin signaling (21, 22) . Interestingly, in the absence of Cyclin A2, we found increased phosphorylation of β-catenin at ser 675 which is targeted by PKA ( Figure 4A ). We therefore determined whether these molecules are involved in the β-catenin dependent pathway regulating EMT induced by Cyclin A2 deficiency. To that purpose, we treated Cyclin A2-depleted cells with AACOCF3 and H89, inhibitors of PLA and PKA, respectively. As demonstrated using qPCR, inhibition of PLA did not affect ECAD, NCAD and fibronectin transcript levels ( Figure 4B, upper panel) , whereas blockage of PKA increased ECAD and decreased fibronectin mRNA levels ( Figure 4B , lower panel; both P < 0.0001). Notably, we observed a statistically significant decrease in NCAD protein expression by both inhibitors (both P = 0.02) although ECAD protein level were unchanged ( Figure 4C ). However, IF analysis revealed that both inhibitors did not improve ECAD localization as compared with vehicle control, although the cell shape of H89-treated cells reverted to a more cuboidal morphology that is typical of epithelial cells ( Figure 4D ). Thus, although inhibition of PLA or PKA was able to revert some EMT parameters, inhibition of PLA or PKA did not result in a full inhibition of Cyclin A2 depletion-induced EMT.
PLC regulates Cyclin A2 deficiency-induced EMT via β-catenin
PLC has been recently reported to play an important role in β-catenin activation through ECAD (19) . We therefore tested whether it could be involved in the EMT we observed in the absence of Cyclin A2. Thus, Cyclin A2-depleted cells were treated with U73122, a specific inhibitor of PLC. We observed an increase in ECAD and a decrease in fibronectin (both P < 0.0001) at the transcriptional level following treatment as compared with vehicle control (Figure 5A ). Although ECAD protein expression exhibited a slight although not statistically significant increase as compared with vehicle control, NCAD was strongly decreased (P = 0.02) in Cyclin A2-depleted cells treated with U73122 ( Figure 5B ). More remarkably, cells harbored a notable improvement in ECAD localization and organization. In particular, the presence of strong and smooth membrane staining indicated nondisrupted cell-cell junctions, much like in normal epithelial cells or sh-scramble cells, as compared with the disorderly and ragged appearance of ECAD observed in vehicle-treated shCycA2 cells ( Figure 5C, arrows) . Further, the U73122-treated cells showed a cuboidal morphology with less cellular extensions. We then checked for β-catenin localization in the same conditions and observed a decreased proportion of its nuclear quantification of this analysis after normalization to GAPDH. (E) qPCR analysis of mRNA levels coding for the Wnt target genes Myc, Snail and Axin2 in shCycA2-treated or not with U73122. mRNA levels were normalized to GUS, HPRT, and TBP and protein levels were normalized to GAPDH. All graphs indicate quantitation of at least three experiments and plotted as fold change in U73122-treated shCycA2 cells compared with vehicle control. *P < 0.05, ***P < 0.001. Scale bars = 20 μm.
localization in the U73122-treated shCycA2 cells in comparison with those treated with DMSO ( Figure 5C ). Further, β-catenin pull-down was performed in control and U73122-treated cells with Cyclin A2 knockdown, and a decrease in β-catenin activity (P = 0.02) was detected in cells with PLC inhibition (Figure 5D ). In line with this, Myc and Snail transcripts were significantly decreased by U73122 treatment. On the other hand, Axin2 which was reduced following Cyclin A2 depletion was found to be slightly increased by treatment with U73122 ( Figure 5E ). Taken together, our findings suggest that EMT induced by Cyclin A2 knockdown is regulated by activation of PLC and β-catenin, mostly independently of the WNT pathway, and can therefore be rescued by inhibition of PLC and β-catenin.
Discussion
This study was performed in corollary to our previous results that showed that Cyclin A2 downregulation plays a major role in inducing EMT and metastasis (5) . However, the mechanisms that govern the transition from an epithelial to a mesenchymal phenotype were not fully elucidated.
Multiple actors are known to regulate the EMT process, including AKT (23) , SAPK/JNK (24, 25) , ERK1/2 (11, 26) and WNT/β-catenin signaling (9) . Indeed, crosstalk between these signal transduction networks are involved in regulating EMT. In insulin-like growth factor-I receptor hyperstimulation of breast epithelial cells, downregulation of AKT1 led to the induction of migration and EMT, which was dependent on the activation of ERK signaling (27) . It has also been shown that in colorectal cancer, EMT was mediated by activation of AKT1, which inhibited its downstream effector GSK3β (25) . In our study, we screened for the activation status of these molecules in order to investigate their contribution to our EMT model (Figure 1 and Supplementary Figure 1 , is available at Carcinogenesis Online). We did not observe any change in AKT1 activation, and SAPK/JNK activity was reduced, which suggested that these components do not have a role in our model. On the other hand, ERK1/2 activities were elevated, but inhibition of this pathway by U0126 treatment did not block EMT. We therefore believe that while these pathways may be dysregulated by Cyclin A2 deficiency, their activities might be involved in the regulation/ induction of other aspects of EMT such as anchorage-independent growth or anoikis resistance in the absence of Cyclin A2.
We also found that, following Cyclin A2 depletion, GSK3β displayed increased phosphorylation ( Figure 1A) , indicating a lower activity, which was paralleled by a nuclear accumulation of active β-catenin (Figure 2) , and its transcriptional activity as tested using the TOP/FOP reporter assay. In this conditions, shCycA2 cells presented almost the same levels of increased luciferase activity expressed as fold change over shScr cells, with or without Wnt3a treatment. However, absolute values of luciferase activity were increased following Wnt3a activation and by comparison with untreated cells (data not shown). GSK3β is a well-known endogenous inhibitor of β-catenin, and inactivation of GSK3β via phosphorylation results in the release and nuclear translocation of β-catenin, where it binds to TCF/lymphocyte enhancer factor and responsive gene promoters to activate transcription of target genes, such as the EMT markers Nanog and Snail as well as Myc. Regulation of β-catenin signaling has been thought to occur predominantly through the WNT pathway. Our findings demonstrated that multiple components of this pathway, including the WNT ligands, its receptors FZD1/2, as well as their endogenous inhibitors SFRPs were increased, suggesting an activation of this WNT pathway ( Figure 2D ). However, inhibition of WNT function using the C59 compound did not fully revert Cyclin A2 depletion-induced EMT. Although NCAD and MMP3 expression were decreased, and the cell shape returned to a more cuboidal morphology, ECAD level as well as its localization and organization did not improve, which indicated that although the cells lost some mesenchymal traits, they did not fully recover their epithelial characteristics (Figure 3) . Therefore, although activated, the WNT pathway was not the major driver of EMT in Cyclin A2-deficient cells. In contrast, directly blocking β-catenin signaling via dnTCF4 did revert the EMT phenotype and restored epithelial markers as well as reducing mesenchymal traits (Figure 3D-F) . This points to divergence of β-catenin and WNT signaling in induction of EMT in our model.
Recent reports have shown that β-catenin signaling may be regulated by other mechanisms (such as by PKA, PLA or PLC) that are independent of the WNT pathway. PKA has been found to directly interact with and stabilize β-catenin through phosphorylation of its Ser 675 (12) . Further, PKA-dependent inactivation of GSK3β through stimulation of G-protein-coupled receptors and the WNT receptors FZDs has been shown to increase β-catenin level and mediated transcription (28) . In our study, inhibition of PKA activity using H89 in Cyclin A2-depleted cells showed an increased in ECAD transcript level while that of fibronectin was decreased. This also correlated with a decrease NCAD protein expression. However, no improvements in ECAD architecture were observed as compared with vehicle-treated control cells although the cell shape was more cuboidal. Therefore, reducing PKA activity only partially reverted the mesenchymal phenotype.
Some isoforms of PLA are also capable of directly binding to and modulating β-catenin function in a WNT-independent manner. Cytosolic PLA2α (cPLA2α) along with peroxisome proliferator-activated receptors were reported to directly interact and form a complex with β-catenin to stabilize its function and facilitate its binding to TCF factors (22) . In another model, Cytosolic PLA2α was demonstrated to increase β-catenin activation and decrease β-catenin/ECAD interaction at the membrane through AKT (21) . On the other hand, an isoform of PLA, phospholipase A2, Group IIA, has recently been shown to be a target gene of β-catenin/TCF, and plays a role in regulating invasion and metastasis of gastric cancer (29) . Thus, PLA isoforms may act to regulate β-catenin function at multiple points. In this work, inhibition of PLA by the addition of AACOCF3 in Cyclin A2-depleted cells reduced NCAD protein expression, although none of the other parameters were affected. In particular, ECAD protein level and organization remained disrupted.
Another well-known pathway that can regulate β-catenin signaling by non-WNT mechanisms involves PLC. PLC can be activated upon stimulation of membrane receptors such G-protein-coupled receptors leading to activation of protein kinase C, phosphorylation of GSK3β and liberation of β-catenin (14) . Further, increased β-catenin signaling through the stimulation of PLC, protein kinase C and ERK1/2 transduction results in higher proliferative potential and migration of breast cancer cells (29) . On the other hand, calcium-mediated signaling has been shown to regulate PLC activation through the ECAD/β-catenin complex at the membrane, which suggests that PLC may be involved in feedback regulation of ECAD and β-catenin. Our findings in this study indeed demonstrate that PLC signal transduction is crucial for β-catenin activation and the associated EMT effects of Cyclin A2 deficiency. This is evidenced by the increase in ECAD mRNA and protein levels, the improved architecture and cell shape, together with the reductions in the mesenchymal markers (NCAD and fibronectin) following PLC inhibition with U73122 in Cyclin A2-depleted cells.
We thus propose a model whereby Cyclin A2 deficiency leads to dual activation of WNT (minor) and PLC (major) pathways that culminate in the inhibition of GSK3β and activation of β-catenin ( Figure 6 ). This leads to differential regulation of its downstream targets that induce EMT, such as upregulation of fibronectin, MMPs, as well as other EMT-associated transcription factors, such as Snail, Slug, Twist2, E47 and E12 involved in ECAD gene repression. In light of these novel findings, we have a better understanding of the mechanisms that take place for the induction of EMT in the absence of Cyclin A2. They reinforce our previous observations that low Cyclin A2 expression could be considered as a prognostic marker for tumor aggressiveness. Supplementary Figures 1-3 and Supplementary Table can 
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